Targeting T-cell Receptor V-region to Treat T-cell Non-Hodgkin Lymphoma
Official title: Targeting the Variable Region of the T-cell Receptor as a Therapeutic Strategy in Clonal T-cell Disease
Funded at Portland VA Medical Center · NIH-11300623 · Data updated 2026-11-12
This NIH grant plans to explore new ways to treat T-cell Non-Hodgkin Lymphoma by targeting the T-cell receptor and overcoming resistance to therapy, with attention to veterans who are disproportionately affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Portland VA Medical Center NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| NIH project number | 1IK2RD001311-01 |
| Project ID | NIH-11300623 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with T-cell Non-Hodgkin Lymphoma, especially those with treatment-resistant disease, may be eligible for future trials or biomarker-guided therapies.
✕Less likely to help
Early-stage research may not yet translate to therapies for all T-NHL patients.
What this research studies
The project uses patient samples and advanced data methods to understand why T-NHL cells resist therapy and to identify drugs that can restore cell death in cancer cells. It combines ex vivo drug testing, single-cell RNA sequencing, and machine learning to map resistance pathways and spot treatment ideas. A second aim looks at overcoming resistance to BCL-2 inhibitors by testing combinations with other FDA-approved agents. If successful, this work could guide personalized treatment approaches for T-NHL patients, including veterans with higher risk exposure.
Why it matters
Potential benefit: If successful, patients with T-NHL may gain more effective, less toxic treatment options and better disease control.
How similar studies have gone: Prior studies with similar multi-omics and drug-screening approaches have shown promise in identifying combination therapies for resistant lymphomas.
Where this research is happening
-
Portland VA Medical Center
Portland, United States Active
Researchers
- Principal investigator: Lucero, Olivia M — Portland VA Medical Center
- Study coordinator: Lucero, Olivia M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.